Gilead Sciences announced on April 8 that it will shift its focus toward integrating three companies it has acquired this year, while remaining open to further strategic acquisitions if the right opportunity arises. The announcement was made during a conference call discussing Gilead’s latest acquisition of Tubulis GmbH.
The company has spent $14.77 billion so far in 2026, marking an increase in its typical pace of mergers and acquisitions. In comparison, Gilead’s only billion-dollar deal in the previous four years was the $4.4 billion purchase of CymaBay Therapeutics in 2024. Historically, Gilead has favored licensing deals with large milestone payments rather than outright purchases.
Chief Financial Officer Andrew Dickinson said, “It’s less likely that we will pursue more sizable M&A this year, although we will always leave the door open to consider strategic acquisitions if a compelling opportunity emerges.” Chief Executive Officer Daniel O’Day added that these recent deals do not signal any lack of confidence in Gilead’s pipeline or major changes to business strategy but are simply the result of finding suitable companies quickly.
The acquisition spree began with Arcellx for $7.59 billion in February, followed by Ouro Medicines for $2.18 billion in March and Tubulis for $5 billion announced on April 7. All three transactions are expected to close during the second quarter of this year.
O’Day emphasized selectivity regarding potential deals: “Given the strength of our existing pipeline and our commitment to financial discipline, the bar for acquisitions is higher than ever before,” he said. He also highlighted successful past integration efforts such as Kite Pharma and noted high demand for recently approved drugs like Livdelzi following earlier acquisitions.
Discussing specific partnerships, O’Day described Arcellx as an asset they know well due to their previous licensing arrangement and pointed out progress towards FDA approval for anito-cel in multiple myeloma treatment later this year. Regarding Tubulis, Chief Medical Officer Dietmar Berger explained how innovative conjugation technologies could expand treatment options beyond cancer into inflammation and virology: “Oncology, ovarian cancer and then other areas in oncology are the first directions, but there is real opportunity to build out and move into inflammation and into virology.”
Berger also addressed Ouro Medicines’ work on T cell engager therapies showing promise against various autoimmune diseases with Phase 3 trials planned as early as 2027.
Looking ahead, O’Day stated there is no uniform approach regarding future partnerships or potential buyouts: “There is no one size fits all for how those partnerships will eventually evolve.”
Industry analysts have noted increased merger activity across big pharmaceutical companies recently but say that Gilead does not feel urgent pressure compared with some peers due to its strong pipeline.
